23092015 PR ladenburg conf_EN
Month: September 2015
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
Ophelie Godon, et al. Vaccine. 2015 Aug 26;33(36):4548-53 – Download the article Publication
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
20150910 – PR 2015 H1 results final
TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.
Elisabeth Quoix, et al. 16th World Conference on Lung Cancer. September 2015, Denver, Colorado Download the poster here Poster Presentation
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
20150908 PR TG4010 IASLC revised – BIS